Thomas Fleming
Impact in
- Oncology top 0.2%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Clinical Biochemistry top 0.1%
- Advanced Glycation End Products research
Papers in
-
- Advanced Glycation End Products research 46
- Physiology 27
- Biochemical effects in animals 12
- Pain Mechanisms and Treatments 11
- Co-authors
- Larry Norton (1 shared paper)W. Eiermann (1 shared paper)Brian Leyland‐Jones (1 shared paper)Dennis J. Slamon (1 shared paper)Mark D. Pegram (1 shared paper)Alex Bajamonde (1 shared paper)Janet Wolter (1 shared paper)Virginia Paton (1 shared paper)
- Journals
- Experimental and Clinical Endocrinology & Diabetes (8 papers)Redox Biology (5 papers)Journal of Biological Chemistry (5 papers)Diabetologia (5 papers)PLoS ONE (4 papers)
- Partner nations
- GermanyUnited StatesUnited Kingdom
In The Last Decade
Thomas Fleming
109 papers receiving 12.2k citations
Thomas Fleming's Hit Papers
Peers
Comparison fields: 5 of 141
- Oncology 5.6k
- Clinical Biochemistry 1.2k
- Cancer Research 1.7k
- Radiology, Nuclear Medicine and Imaging 2.2k
- Sensory Systems 239
Countries citing papers authored by Thomas Fleming
This map shows the geographic impact of Thomas Fleming's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Fleming with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Fleming more than expected).
Fields of papers citing papers by Thomas Fleming
This network shows the impact of papers produced by Thomas Fleming. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Fleming. The network helps show where Thomas Fleming may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas Fleming, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 112 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 Hit paper breakdown → | 2001 | 8935 |
| 2 | 2015 | 258 | |
| 3 | 2018 | 185 | |
| 4 | 2017 | 178 | |
| 5 | 2012 | 166 | |
| 6 | 2018 | 134 | |
| 7 | 2013 | 115 | |
| 8 | 2010 | 110 | |
| 9 | 2010 | 103 | |
| 10 | 2019 | 97 | |
| 11 | 2013 | 76 | |
| 12 | 2012 | 69 | |
| 13 | 2016 | 68 | |
| 14 | 2014 | 64 | |
| 15 | 2015 | 64 | |
| 16 | 2016 | 59 | |
| 17 | 2018 | 57 | |
| 18 | 2014 | 55 | |
| 19 | 2020 | 50 | |
| 20 | 2022 | 50 |
About Thomas Fleming
Thomas Fleming is a scholar working on Clinical Biochemistry, Physiology, Molecular Biology, Endocrinology, Diabetes and Metabolism and Cell Biology, having authored 112 papers that have together received 12.6k indexed citations. Recurring topics across this work include Advanced Glycation End Products research (46 papers), Biochemical effects in animals (12 papers), Pain Mechanisms and Treatments (11 papers), Natural Antidiabetic Agents Studies (7 papers), Ion Channels and Receptors (6 papers), Metabolism, Diabetes, and Cancer (5 papers), Alcohol Consumption and Health Effects (5 papers) and Genetics, Aging, and Longevity in Model Organisms (5 papers). The work is most often cited by research in Oncology (5.6k citations), Clinical Biochemistry (1.2k citations), Cancer Research (1.7k citations), Radiology, Nuclear Medicine and Imaging (2.2k citations) and Sensory Systems (239 citations). Thomas Fleming has collaborated with scholars based in Germany, United States and United Kingdom. Frequent co-authors include Larry Norton, W. Eiermann, Brian Leyland‐Jones, Dennis J. Slamon, Mark D. Pegram, Alex Bajamonde, Janet Wolter, Virginia Paton, José Baselga and Steven Shak. Their work appears in journals such as Experimental and Clinical Endocrinology & Diabetes, Redox Biology, Journal of Biological Chemistry, Diabetologia and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.